My Market Wizard

180 Life Sciences Corp. 8-K Analysis & Summary – 2/21/2025

⚠️This is not investment advice.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️

180 Life Sciences Corp.
,

Filing date:

02/21/2025

TLDR:

180 Life Sciences Corp. appointed Eric R. Van Lent as Chief Accounting Officer, replacing Blair Jordan, and entered into related consulting agreements and stock awards.

ELI5:

A company hired a new head of accounting and gave stock to its board members. They also made a deal with their CEO for his continued service.

Accession #:

0001213900-25-016103

Published on

Analyst Summary

  • Eric R. Van Lent appointed as Chief Accounting Officer (Principal Accounting/Financial Officer) effective February 15, 2025.
  • Blair Jordan stepped down as Principal Accounting/Financial Officer on February 15, 2025, remaining as Chief Executive Officer.
  • Executive Consulting Agreement entered into with Eric R. Van Lent and EVL Consulting, LLC, paying $8,000 per month for an average of 10 hours of work per week.
  • Executive Consulting Agreement with Blair Jordan Strategy and Finance Consulting Inc. provides $240,000 per year for Blair Jordan’s services as Chief Executive Officer.
  • 160,000 shares of restricted common stock granted to Blair Jordan, vesting in two tranches in 2026.
  • 65,000 shares of restricted common stock issued to each of the four non-executive members of the Board of Directors, vesting in two tranches in 2025.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️